Clearance of Chikungunya virus infection in lymphoid tissues is promoted by treatment with an agonistic anti-CD137 antibody.

@article{Hong2019ClearanceOC,
  title={Clearance of Chikungunya virus infection in lymphoid tissues is promoted by treatment with an agonistic anti-CD137 antibody.},
  author={Jun Pyu Hong and Mary K McCarthy and Bennett J Davenport and Thomas E Morrison and Michael S Diamond},
  journal={Journal of virology},
  year={2019}
}
CD137, a member of the tumor necrosis factor receptor superfamily of cell surface proteins, acts as a costimulatory receptor on T cells, natural killer cells, B cell subsets, and some dendritic cells. Agonistic anti-CD137 monoclonal antibody (mAb) therapy has been combined with other chemotherapeutic agents in human cancer trials. Based on its ability to promote tumor clearance, we hypothesized that anti-CD137 mAb might activate immune responses and resolve chronic viral infections. We… CONTINUE READING